论文部分内容阅读
中晚期癌症由于肿瘤本身转移、侵犯神经、放疗损伤和化疗药物毒性等,常发生相关的神经病理性疼痛,临床表现为阵发性、烧灼样、刀割样、搏动性、电击样、针刺样疼痛。部分伴有感觉缺失,很难用常规镇痛药物控制疼痛。普通的水杨酸类止痛药和某些吗啡类止痛药对癌症神经病理性疼痛止痛效果不佳,从而严重影响到患者的生活质量,甚至威胁患者的生存[1]。美沙酮是合成的一种阿片受体激动剂,也是一种非竞争性N-甲基-D-天冬氨酸受体(NMDA受体)拮抗剂,从而对治疗神经病理性疼痛有独特的优势,不良反应较羟考酮缓释片轻。我们选择30例口服大剂量羟考酮缓释片止痛效果不满意的癌症神经病理性疼痛患者转换为美沙酮
In the advanced stage of cancer due to tumor metastasis, invasion of nerves, radiation injury and chemotherapy drug toxicity, often associated with neuropathic pain, clinical manifestations of paroxysmal, burning kind, knife-like, pulsatility, shock like, acupuncture-like pain. Part of the sensory loss, it is difficult to control pain with conventional analgesics. Common salicylate painkillers and some morphine painkillers have poor analgesic effects on cancer neuropathic pain, which can seriously affect the patient’s quality of life and even threaten the patient’s survival [1]. Methadone is a synthetic opioid receptor agonist and a non-competitive N-methyl-D-aspartate receptor (NMDA receptor) antagonist that has unique advantages in the treatment of neuropathic pain, Adverse reactions than oxycodone sustained release tablets light. We selected 30 cases of oral administration of high doses of oxycodone sustained release tablets analgesic effect of cancer neuropathic pain were converted to methadone